<DOC>
	<DOCNO>NCT01638676</DOCNO>
	<brief_summary>The main purpose study evaluate safety Vemurafenib combination Metformin melanoma patient . The phase II part study also evaluate clinical activity combine regiment . Based pre-clinical study phase I trial , investigator hypothesize combination FDA-approved non-toxic dose oral Metformin Vemurafenib yield little toxicity improve clinical outcome term objective response rate survival metastatic melanoma patient .</brief_summary>
	<brief_title>A Phase I/II Trial Vemurafenib Metformin Melanoma Patients</brief_title>
	<detailed_description>This Phase I/II study . Phase I evaluate safety FDA-approved Vemurafenib ( 960 mg orally , daily ) combination Metformin ( 500 mg orally , twice daily 2 week , 850 mg orally , twice daily ) patient unresectable Stage IIIC Stage IV melanoma . Phase II evaluate clinical activity combine Vemurafenib/Metformin regimen . The safety profile combine Vemurafenib/Metformin regimen monitor phase . The treatment period consist 28-day cycle progression unacceptable toxicity occur .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>1 . Male female patient ≥ 18 year age ; 2 . Patients histological confirm BRAFV600E melanoma ( Stage IIIC Stage IV , American Joint Commission Cancer ) ; 3 . Eastern Cooperative Oncology Group ( ECOG ) Performance Status ( PS ) 0 2 ; 4 . Life expectancy ≥ 3 month ; 5 . At least 1 site radiographically measurable disease RECIST 1.1 6 . Adequate hematologic , renal , liver function define laboratory value perform within 42 day prior initiation dosing : Absolute neutrophil count ( ANC ) ≥ 1.0 x 109/L ; Platelet count ≥ 50 x 109/L ; Hemoglobin ≥ 8 g/dL ; Serum creatinine ≤ 2 x upper limit normal ( ULN ) Total serum bilirubin ≤ 3 x ULN ; Serum aspartate transaminase ( AST/SGOT ) serum alanine transaminase ( ALT/SGPT ) ≤ 3x ULN , ≤ 4 x ULN liver metastases present . 7 . Fertile male use effective method contraception treatment least 3 month completion treatment , direct physician ; 8 . Premenopausal females female &lt; 2 year onset menopause negative pregnancy test Screening . Premenopausal females must agree use acceptable method birth control time negative pregnancy test 90 day last dose study drug . Females nonchildbearing potential may include either surgically sterile postmenopausal ≥ 1 year ; 9 . Before study entry , write informed consent must obtain patient prior perform studyrelated procedure . 1 . Prior treatment Vemurafenib ; 2 . Known hypersensitivity Metformin component ; 3 . Previous progression melanoma Metformin ; 4 . Received radiotherapy non CNS disease within 2 week prior commence study treatment recover side effect radiationrelated toxicity Grade ≤ 1 , except alopecia ; 5 . Pregnant , breastfeeding , refuse double barrier contraception , oral contraceptive , avoidance pregnancy measure ; 6 . Have uncontrolled infection medical condition could interfere conduct study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Unresectable melanoma</keyword>
	<keyword>Stage IIIC Stage IV BRAFV600E+ Melanoma</keyword>
</DOC>